Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Case report

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer

Riccardo Samaritani1, Giacomo Corrado2*, Enrico Vizza2 and Carlo Sbiroli2

Author Affiliations

1 Division of Medical Oncology, San Carlo IDI Sanità Hospital, Rome, Italy

2 Division of Gynaecologic Oncology, National Cancer Institute "Regina Elena", Rome, Italy

For all author emails, please log on.

BMC Cancer 2007, 7:65  doi:10.1186/1471-2407-7-65

Published: 15 April 2007

Abstract

Background

Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.

Case presentation

We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan.

The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects. She was well during the chemotherapy and lived a normal working and social life.

Conclusion

We think that use of low dose of oral CTX should be investigated further as a strategy against tumour progression after standard chemotherapy in patients who are platinum resistant with poor performance status.